A tablet asks for no needle, no sharps container and no space in the refrigerator, and it is sold on exactly those terms. Two claims tend to ride along with that pitch. One is that the pill has been shown to match the injection. The other is that it costs less. The first is close to true and not quite; the second is not reliably true at all — see what sellers charge for each form.
There is a third thing the pitch leaves out, and it is the one that matters most. The tablets in the published trials were a manufactured product. A pharmacy-prepared oral preparation is something else, and the compounding question lands harder on this format than on injections.
What the oral trials measured
OASIS 1 randomized 667 adults with overweight or obesity and without diabetes to oral semaglutide 50 mg once daily or matching placebo for 68 weeks. Estimated mean body-weight change was −15.1% against −2.4% on placebo, a treatment difference of 12.7 percentage points.[1]
OASIS 4 tested half that daily amount. It randomized 307 adults 2:1 to oral semaglutide 25 mg or placebo, and mean weight change to week 64 was −13.6% against −2.2%.[2] Both trials were placebo-controlled, double-blind and industry-funded.
Responder rates give the same picture in a more usable form. In OASIS 1, 85% of participants on the tablet lost at least 5% of body weight against 26% on placebo, 69% lost at least 10% against 12%, and 34% lost at least 20% against 3%.[1] Those are the thresholds a prescriber tends to care about, and the separation from placebo is not subtle.
The injectable reference point is STEP 1, in which once-weekly semaglutide 2.4 mg produced −14.9% over 68 weeks.[3] Those three figures sit within a point and a half of one another. It is worth being exact about what that does and does not establish.
Nobody has run the head-to-head
These are three trials, not three arms. They enrolled different people, at different sites, over slightly different windows, and none of them was designed to detect a difference between the two formats. Their placebo arms alone spanned −2.2% to −2.4%, which is a reminder of how much ordinary variation separate populations carry.
So the honest summary is narrow and still useful: the daily tablet reached the same general neighborhood as the weekly injection in trials that each beat their own placebo comfortably. A gap of a percentage point between two unlinked trials is not a ranking. Treat the formats as clinically comparable options rather than as a winner and a runner-up.
Why the milligram figures do not compare
A peptide is badly absorbed from the gut, which is why the injectable versions arrived first. An oral product works around that with a formulation built to carry the molecule across the gut wall, and only a small fraction of what is swallowed reaches the bloodstream. That is the reason the doses look so mismatched: 25 or 50 mg taken daily against 2.4 mg injected weekly.
The practical consequence is that a price-per-milligram comparison across the two formats is meaningless arithmetic. Compare a monthly cost with a monthly cost, and treat the strengths on the two labels as separate units. The same caution applies to a seller that quotes one figure and leaves the format unstated, which is common enough that the oral board prices each seller on its own oral product rather than its injectable one.
The compounded tablet was in no pivotal trial
Every number above came from a manufactured tablet, made to one specification, taken on a fixed daily routine under trial conditions. A compounded oral or sublingual preparation, prepared by a pharmacy against a prescription, is a different formulation. How much of it is absorbed has not been published, and none of the pivotal trials covered it.
That gap is wider than the equivalent one for injections. A compounded injectable at least matches the trial route and uses the same dose units, so the trial evidence describes something recognizable. With an oral preparation, absorption is the hard part, and the formulation is precisely what changes. The regulatory position is the same in both cases and is set out in the compounding article.
The cheaper route is not consistently the oral one
Sellers set their oral and injectable prices independently, and the direction of the gap varies from company to company. Some charge more for their own tablet than for their own vial; some charge less; a few price the two within a few dollars. Nothing about the format predicts which, and a category-level assumption applied to a specific seller is how people end up paying a premium they did not expect.
The comparison that works is narrow: take one seller, read both of its own figures, and compare the pair. Across the wider market, the standing monthly rates and the individual seller write-ups carry each format separately for the same reason.
What should actually decide it
Adherence, mostly. A weekly injection is one event to remember and a barrier some people never get past. A daily tablet removes the needle and replaces it with a routine that has to hold every morning for a year. Those are different burdens and different people fail at them.
Tolerability is the other input, and swallowing the drug does not remove it. Gastrointestinal effects were reported by 80% of participants on the 50 mg tablet in OASIS 1 against 46% on placebo, mostly mild to moderate.[1] That is the same class of effect the injections produce, so what the trials recorded is worth reading before the format question feels settled. The molecule decision sits underneath both and is covered in the evidence comparison. Whichever format you land on, how a seller prices the climb toward a maintenance dose will move a year’s bill more than the format itself — see sellers that hold one price.